WO2007090882A3 - Pharmaceutical extended release compositions comprising pramipexole - Google Patents

Pharmaceutical extended release compositions comprising pramipexole Download PDF

Info

Publication number
WO2007090882A3
WO2007090882A3 PCT/EP2007/051257 EP2007051257W WO2007090882A3 WO 2007090882 A3 WO2007090882 A3 WO 2007090882A3 EP 2007051257 W EP2007051257 W EP 2007051257W WO 2007090882 A3 WO2007090882 A3 WO 2007090882A3
Authority
WO
WIPO (PCT)
Prior art keywords
extended release
pramipexole
release compositions
pharmaceutical extended
composition
Prior art date
Application number
PCT/EP2007/051257
Other languages
French (fr)
Other versions
WO2007090882A2 (en
Inventor
Georg Boeck
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Georg Boeck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Georg Boeck filed Critical Boehringer Ingelheim Int
Publication of WO2007090882A2 publication Critical patent/WO2007090882A2/en
Publication of WO2007090882A3 publication Critical patent/WO2007090882A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An extended release co mposit ion is disclosed which comprises the active compound pramipexole and provides a selected release profile. Preferably, the composition does not exhibit a lag phase of more than 1 hour. The composition is for suitable for oral administration. The invention also provides a method for achieving a 5 selected release profile, optionally by combining an extended release dose fraction and an immediate release dose fraction.
PCT/EP2007/051257 2006-02-10 2007-02-09 Pharmaceutical extended release compositions comprising pramipexole WO2007090882A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06002773 2006-02-10
EP06002773.7 2006-02-10

Publications (2)

Publication Number Publication Date
WO2007090882A2 WO2007090882A2 (en) 2007-08-16
WO2007090882A3 true WO2007090882A3 (en) 2007-12-13

Family

ID=38057461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/051257 WO2007090882A2 (en) 2006-02-10 2007-02-09 Pharmaceutical extended release compositions comprising pramipexole

Country Status (1)

Country Link
WO (1) WO2007090882A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377977B2 (en) 2004-08-13 2013-02-19 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US8715728B2 (en) 2004-08-13 2014-05-06 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (en) 2006-05-16 2012-01-15 Knopp Neurosciences Inc COMPOSITIONS OF R(+)- AND S(-)-PRAMIPEXOLE AND METHOD FOR THEIR USE
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2137171A4 (en) 2007-03-14 2010-05-19 Knopp Neurosciences Inc Synthesis of chirally purified substituted benzothiazole diamines
US20090304794A1 (en) * 2008-06-09 2009-12-10 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
AU2010234244A1 (en) * 2009-04-09 2011-10-13 Purdue Pharma Once-daily oral IR/CR pramipexole formulation
AU2010266285A1 (en) * 2009-07-02 2012-02-09 Supernus Pharmaceuticals, Inc. A method of treatment of a neurological disorder
TR201001862A1 (en) * 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Controlled release pramipexole formulations.
US20130209553A1 (en) * 2010-04-15 2013-08-15 Cadila Healthcare Limited Extended release pharmaceutical compositions of pramipexole
EP2380560A1 (en) * 2010-04-22 2011-10-26 ratiopharm GmbH Matrix tablets containing pramipexol
WO2011148243A1 (en) 2010-05-24 2011-12-01 Lupin Limited Extended release formulation of pramipexole
KR101307334B1 (en) * 2010-07-02 2013-09-12 주식회사 바이오파마티스 Sustained-release pharmaceutical composition comprising pramipexole or pharmaceutically acceptable salt thereof having improved stability
DE102010050457A1 (en) * 2010-10-22 2012-04-26 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Improved pharmaceutical starter pellets
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
RS61539B1 (en) 2013-07-12 2021-04-29 Knopp Biosciences Llc Treating elevated levels of eosinophils and/or basophils
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
ES2813674T3 (en) 2013-08-13 2021-03-24 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010982A1 (en) * 2002-07-25 2004-02-05 Pharmacia Corporation Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former
WO2004010999A1 (en) * 2002-07-25 2004-02-05 Pharmacia Corporation Pramipexole once-daily dosage form
WO2004010997A1 (en) * 2002-07-25 2004-02-05 Pharmacia Corporation Sustained-release tablet composition of pramipexole
WO2006015942A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006015943A2 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006046256A1 (en) * 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
WO2007002518A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
WO2007022182A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
WO2007054976A2 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010982A1 (en) * 2002-07-25 2004-02-05 Pharmacia Corporation Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former
WO2004010999A1 (en) * 2002-07-25 2004-02-05 Pharmacia Corporation Pramipexole once-daily dosage form
WO2004010997A1 (en) * 2002-07-25 2004-02-05 Pharmacia Corporation Sustained-release tablet composition of pramipexole
WO2006015942A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006015943A2 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006015944A2 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
WO2006046256A1 (en) * 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
WO2007002518A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
WO2007022182A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
WO2007054976A2 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377977B2 (en) 2004-08-13 2013-02-19 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US8715728B2 (en) 2004-08-13 2014-05-06 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
WO2007090882A2 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
WO2007090882A3 (en) Pharmaceutical extended release compositions comprising pramipexole
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2008027542A3 (en) 5-substituted isoindoline compounds
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2008013838A3 (en) Pyridizinone derivatives
WO2006025070A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
WO2006112551A3 (en) A THERAPEUTIC AGENT FOR Aβ RELATED DISORDERS
WO2006131591A3 (en) An entacapone-containing oral dosage form
WO2007135527A3 (en) Benzimidazolyl compounds
WO2009022354A3 (en) Modified dosage forms of tacrolimus
WO2005085236A3 (en) Caspase inhibitors and uses thereof
WO2007075794A3 (en) Oral formulations comprising tigecycline
PT2049480E (en) 2-arylindole derivatives as mpges-1 inhibitors
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
WO2004105773A3 (en) Use of s1p
WO2009145591A3 (en) Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof
WO2008101173A3 (en) Biodegradable compositions and materials
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
WO2007027519A3 (en) Compositions and methods for darkening keratinous fibers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07712196

Country of ref document: EP

Kind code of ref document: A2